Stock listing
NASDAQ:PRME Prime Medicine, Inc. Stock
Home listing (NASDAQ) of Prime Medicine, Inc.
Follow Prime Medicine, Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:PRME
$4.19 USD -0.08 (-1.9%)
Close on Nov 16, 2026
- Day range
- $4.10 – $4.36 USDNov 16, 2026
- Volume
- 6.74M sharesNov 16, 2026
- Market cap
- $760.0M USDAt the close on Nov 16, 2026 · price × 181.4M shares outstanding
- 52-week range
- $2.67 – $5.91 USDLowest and highest trades, Nov 17, 2025 – Nov 16, 2026
- Traded on an average day
- $17.40M USDMedian day 3.68M shares · last 3 months, Aug 17, 2026 – Nov 16, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:PRME · Home | $4.19 USD | -0.08 (-1.9%) | 6,735,460 | $4.12 | $4.36 | $4.10 | $4.27 | Close on Nov 16, 2026 |
Daily closes
Last 3 months, Aug 17, 2026 – Nov 16, 2026 · NASDAQ:PRME · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $4.19 | -0.08 | -1.9% | $4.12 | $4.36 | $4.10 | 6,735,460 | |
| $4.27 | +0.38 | +9.8% | $4.05 | $4.426 | $4.01 | 5,953,488 | |
| $3.89 | -0.41 | -9.5% | $4.04 | $4.13 | $3.73 | 7,167,410 | |
| $4.30 | +0.40 | +10.3% | $3.93 | $4.35 | $3.80 | 12,842,890 | |
| $3.90 | -0.40 | -9.3% | $4.19 | $4.225 | $3.77 | 4,502,102 | |
| $4.30 | -0.35 | -7.5% | $4.70 | $4.70 | $4.22 | 3,477,932 | |
| $4.65 | +0.20 | +4.5% | $4.53 | $4.695 | $4.455 | 3,058,654 | |
| $4.45 | -0.52 | -10.5% | $4.86 | $4.91 | $4.301 | 4,737,120 | |
| $4.97 | +0.42 | +9.2% | $4.75 | $5.12 | $4.59 | 4,394,906 | |
| $4.55 | +0.11 | +2.5% | $4.50 | $4.885 | $4.435 | 4,115,219 | |
| $4.44 | -0.28 | -5.9% | $4.74 | $4.84 | $4.361 | 4,122,637 | |
| $4.72 | -0.52 | -9.9% | $5.03 | $5.20 | $4.675 | 6,556,079 | |
| $5.24 | -0.12 | -2.2% | $5.21 | $5.91 | $5.19 | 10,327,326 | |
| $5.36 | +1.01 | +23.2% | $4.245 | $5.43 | $4.11 | 15,165,766 | |
| $4.35 | +0.74 | +20.5% | $3.62 | $4.41 | $3.57 | 8,810,312 | |
| $3.61 | -0.06 | -1.6% | $3.66 | $3.70 | $3.57 | 2,508,756 | |
| $3.67 | -0.06 | -1.6% | $3.70 | $3.70 | $3.38 | 4,560,300 | |
| $3.73 | -0.08 | -2.1% | $3.68 | $3.92 | $3.62 | 4,657,500 | |
| $3.81 | -0.11 | -2.8% | $3.92 | $4.005 | $3.795 | 2,436,400 | |
| $3.92 | +0.09 | +2.3% | $3.75 | $4.05 | $3.73 | 3,694,600 | |
| $3.83 | +0.36 | +10.4% | $3.56 | $3.87 | $3.49 | 4,250,500 | |
| $3.47 | -0.14 | -3.9% | $3.55 | $3.605 | $3.41 | 4,386,000 | |
| $3.61 | +0.48 | +15.3% | $3.12 | $3.65 | $3.06 | 6,299,900 | |
| $3.13 | -0.19 | -5.7% | $3.21 | $3.22 | $3.045 | 4,236,500 | |
| $3.32 | -0.29 | -8.0% | $3.61 | $3.61 | $3.27 | 4,058,100 | |
| $3.61 | -0.38 | -9.5% | $3.95 | $3.965 | $3.58 | 3,132,900 | |
| $3.99 | +0.41 | +11.5% | $3.57 | $4.14 | $3.54 | 8,064,200 | |
| $3.58 | -0.32 | -8.2% | $3.83 | $3.898 | $3.52 | 7,721,200 | |
| $3.90 | +0.40 | +11.4% | $3.36 | $4.02 | $3.30 | 11,194,100 | |
| $3.50 | +0.29 | +9.0% | $3.56 | $3.718 | $3.26 | 12,014,000 | |
| $3.21 | +0.23 | +7.7% | $3.00 | $3.26 | $2.88 | 4,716,900 | |
| $2.98 | -0.01 | -0.3% | $3.05 | $3.075 | $2.92 | 2,108,600 | |
| $2.99 | -0.065 | -2.1% | $3.05 | $3.105 | $2.98 | 2,825,800 | |
| $3.055 | -0.035 | -1.1% | $3.11 | $3.19 | $3.02 | 3,126,900 | |
| $3.09 | +0.215 | +7.5% | $2.93 | $3.135 | $2.88 | 3,605,600 | |
| $2.875 | -0.025 | -0.9% | $2.85 | $2.92 | $2.77 | 3,681,400 | |
| $2.90 | -0.17 | -5.5% | $3.42 | $3.44 | $2.875 | 7,116,300 | |
| $3.07 | -0.06 | -1.9% | $3.11 | $3.13 | $2.99 | 4,485,400 | |
| $3.13 | -0.41 | -11.6% | $3.53 | $3.53 | $3.12 | 3,331,900 | |
| $3.54 | +0.35 | +11.0% | $3.22 | $3.565 | $3.20 | 2,717,700 | |
| $3.19 | +0.07 | +2.2% | $3.19 | $3.27 | $3.10 | 2,946,300 | |
| $3.12 | -0.02 | -0.6% | $3.13 | $3.17 | $3.045 | 4,672,500 | |
| $3.14 | +0.14 | +4.7% | $3.11 | $3.39 | $3.10 | 3,252,700 | |
| $3.00 | -0.14 | -4.5% | $3.18 | $3.22 | $2.93 | 3,290,400 | |
| $3.14 | -0.04 | -1.3% | $3.18 | $3.22 | $3.00 | 2,573,100 | |
| $3.18 | +0.05 | +1.6% | $3.10 | $3.28 | $3.10 | 1,616,200 | |
| $3.13 | -0.22 | -6.6% | $3.38 | $3.44 | $3.10 | 3,075,700 | |
| $3.35 | -0.12 | -3.5% | $3.37 | $3.42 | $3.31 | 2,386,300 | |
| $3.47 | -0.09 | -2.5% | $3.47 | $3.535 | $3.29 | 4,223,300 | |
| $3.56 | -0.14 | -3.8% | $3.65 | $3.65 | $3.41 | 3,600,800 | |
| $3.70 | -0.01 | -0.3% | $3.83 | $3.86 | $3.65 | 1,618,700 | |
| $3.71 | +0.04 | +1.1% | $3.70 | $3.72 | $3.49 | 2,311,700 | |
| $3.67 | +0.10 | +2.8% | $3.50 | $3.705 | $3.47 | 2,473,900 | |
| $3.57 | -0.02 | -0.6% | $3.54 | $3.71 | $3.48 | 2,453,000 | |
| $3.59 | -0.02 | -0.6% | $3.54 | $3.635 | $3.46 | 2,092,600 | |
| $3.61 | -0.03 | -0.8% | $3.57 | $3.70 | $3.48 | 2,693,500 | |
| $3.64 | +0.06 | +1.7% | $3.55 | $3.665 | $3.48 | 1,832,800 | |
| $3.58 | -0.13 | -3.5% | $3.66 | $3.66 | $3.435 | 1,950,200 | |
| $3.71 | +0.46 | +14.2% | $3.30 | $3.71 | $3.285 | 3,320,951 | |
| $3.25 | -0.14 | -4.1% | $3.38 | $3.40 | $3.195 | 2,267,579 | |
| $3.39 | +0.15 | +4.6% | $3.26 | $3.49 | $3.24 | 3,597,000 | |
| $3.24 | -0.30 | -8.5% | $3.43 | $3.50 | $3.20 | 3,797,900 | |
| $3.54 | +0.49 | +16.1% | $3.29 | $3.59 | $3.25 | 6,791,300 | |
| $3.05 | -0.12 | -3.8% | $3.10 | $3.199 | $3.02 | 1,271,000 | |
| $3.17 | +0.08 | +2.6% | $3.07 | $3.19 | $3.021 | 1,500,700 |
- Ticker
- NASDAQ:PRME
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 12, 2026
Prime Medicine Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
Latest earnings call · Nov 16, 2026
Prime Medicine (NASDAQ:PRME) Q3 2026 Earnings Call
Replay and transcript
Latest deck · Nov 10, 2026
Investor Presentation (November 2026)
Investor deck · 44 slides
Calls
Replays
Prime Medicine (NASDAQ:PRME) Q3 2026 Earnings Call
Mon, Nov 16, 2026 · 4:00 PM ET
Watch Transcript
Latest news
Prime Medicine Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
Nov 12, 2026
Closed $4.27 (+9.8%) on Nov 13, 2026
Prime Medicine Reports Third Quarter 2026 Financial Results and Provides Business Updates
Nov 12, 2026
Closed $4.27 (+9.8%) on Nov 13, 2026
Prime Medicine Announces Pricing of Public Offering of Common Stock
Nov 10, 2026
Closed $4.30 (+10.3%) on Nov 11, 2026
Prime Medicine Announces Proposed $125.0 Million Public Offering of Common Stock
Nov 10, 2026
Closed $4.30 (+10.3%) on Nov 11, 2026
Prime Medicine to Present at Jefferies Global Healthcare Conference
Nov 9, 2026
Closed $4.30 (-7.5%) on Nov 9, 2026
Prime Medicine Announces First Patient Dosed in Global Phase 1/2 Clinical Trial of PM577a for H1069Q-Mutated Wilson Disease
Oct 5, 2026
Closed $3.21 (+7.7%) on Oct 5, 2026
Prime Medicine Announces U.S. FDA Clearance of Investigational New Drug Application for PM647 in Alpha-1 Antitrypsin Deficiency
Sep 24, 2026
Closed $2.90 (-5.5%) on Sep 25, 2026
Prime Medicine Reports Second Quarter 2026 Financial Results and Provides Business Updates
Aug 6, 2026
Closed $2.95 (-4.2%) on Aug 6, 2026
Prime Medicine Announces U.S. FDA Clearance of Investigational New Drug Application for PM577a in H1069Q-mutated Wilson Disease
Jul 23, 2026
Closed $2.95 (-0.7%) on Jul 24, 2026
Prime Medicine Announces Positive Resolution to Arbitration with Beam Therapeutics
Jul 8, 2026
Closed $4.62 (+15.8%) on Jul 8, 2026
Financings
Public offering of common stock
Nov 12, 2026
Closed: US$143.7M raised · US$3.5 a share · Jefferies +4
Dealers: Jefferies (co-lead), TD Cowen (co-lead), Goldman Sachs & Co. LLC (co-lead), Oppenheimer & Co., LifeSci Capital
Use of proceeds: Strengthen the balance sheet and advance its programs through key clinical milestones
Announced Nov 10, 2026 · Announced Nov 11, 2026 · Closed Nov 12, 2026
Public offering of common stock
Aug 1, 2025
Closed: US$144.2M raised · US$3.3 a share · TD Cowen +1
Dealers: TD Cowen (co-lead), BMO Capital Markets (co-lead)
Buyers: Cystic Fibrosis Foundation (1,818,181 shares of common stock)
Announced Jul 30, 2025 · Announced Jul 31, 2025 · Closed Aug 1, 2025
Strategic investment of equity investment
Jul 16, 2025
Announced: US$6M
Buyers: Cystic Fibrosis Foundation ($6 million equity investment in the first tranche of up to $24 million in funding)
Use of proceeds: Accelerate development of Prime Editors to permanently correct cystic fibrosis-related lung disease
Decks
Investor Presentation (November 2026)
Investor deck · 44 slides · Nov 10, 2026
Investor Presentation (October 2026)
Investor deck · 44 slides · October 2026
Investor Presentation (March 2026)
Investor deck · 41 slides · Mar 3, 2026
Investor Presentation (January 2026)
Investor deck · 41 slides · Jan 12, 2026
Prime Medicine, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 19 in the last 12 months · 39 in all · newest Nov 12, 2026 · oldest 2024
- Calls
- 1 call with a replay · 1 with a transcript · latest Nov 16, 2026
- Decks
- 21 decks · latest Nov 10, 2026
Where Prime Medicine, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:PRME · Home listing · This page | NASDAQ | United States | USD |
| BOATS:PRME | BOATS | United States | USD |
Log in to ask 6ix AI your own questions about Prime Medicine, Inc.